CD274 and neoplasm: With a median follow-up time of 11.7 months, the ORR in 77 patients was 14.3% (95% CI: 7.4 to 24.1%), including 2.6% of the patients with CRs and 11.7% of patients with PRs, whereas no response was observed in patients without PD-L1 expression in tumor cells.